Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...

From Corpus Christie, Texas, Jenn Mirabal, an MDA staff member and mother of a child living with Duchenne muscular dystrophy ...

Get Tuesday's top stock gainers and losers, plus market updates on Hims & Hers, Sarepta, crypto stocks, and Palantir.

Sarepta Therapeutics ( SRPT) shares fell after its late-stage trial for two gene therapies, AMONDYS 45 (casimersen) and VYONDYS 5 (golodirsen), aimed at treating Duchenne muscular dystrophy, did not ...

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their ...

Ad hoc announcement pursuant to Art. 53 LR Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen ...

Shares of Sarepta Therapeutics ($SRPT) plunged after the company reported disappointing results from a key trial of its Duchenne muscular ...

Sarepta shares are plunging in extended trading Monday after the company reports third-quarter results and provided an update on its ESSENCE study.